Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates

Experimental and Molecular Pathology
Amjad MahasnehEshraq Jamal

Abstract

Colorectal cancer (CRC) is the third most prevalent cancer in the world. Globally, it has been estimated that about 1.4 million new cases of colorectal cancer are diagnosed every year. CRC is a multifactorial disease that arises due to genetics as well as epigenetic alterations in a number of oncogenes, tumor suppressor genes, mismatch repair genes, as well as cell cycle regulating genes in colon mucosal cells. These molecular alterations have been considered as potential CRC biomarkers because they can provide the physicians with diagnostic, prognostic and treatment response information. The goal is to identify relevant, cheap and applicable biomarkers that contribute to patient management decisions, resulting in direct benefits to patients. In this review, we will outline the most currently available and developing tumor tools, and blood molecular biomarkers. Also, we will illustrate their diagnostic, therapeutic and prognostic applications.

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Mar 23, 2011·Current Colorectal Cancer Reports·Graeme P Young, Linda J W Bosch
Aug 13, 2013·Virchows Archiv : an International Journal of Pathology·Jens NeumannAndreas Jung
Apr 30, 2017·World Journal of Gastrointestinal Oncology·Michail GalanopoulosGerassimos J Mantzaris

❮ Previous
Next ❯

Citations

Aug 23, 2017·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Yang WangWei Li
Oct 20, 2018·Oncology Letters·Zijian LiuQuanxiang Luo
Sep 25, 2019·International Journal of Molecular Sciences·Hsin-Hua ChungYu-Lueng Shih
Sep 25, 2018·Journal of Cellular Biochemistry·Hamid Cheshomi, Maryam M Matin
Aug 12, 2020·Journal of Cancer Research and Clinical Oncology·Yu LiZhuoli Zhang
Nov 22, 2018·Lipids in Health and Disease·Tong LiJiusheng Deng
Dec 8, 2017·BioMed Research International·Gaia PelusoNicola Carlomagno
Oct 9, 2020·International Journal of Colorectal Disease·Eivor Alette LaugsandFrank Skorpen
Mar 6, 2021·Analytical and Bioanalytical Chemistry·Wenxian ZhangChonghai Xu
Aug 29, 2021·Pharmaceutics·Ana Luiza C de S L OliveiraRaimundo Fernandes de Araújo Junior
Sep 22, 2021·Biomarkers in Medicine·Siyu HeMei Lin
Sep 5, 2021·Chemical Biology & Drug Design·Masomeh MalekiMaryam Majidinia
Apr 11, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Chun FengYanjie Zhang
Nov 10, 2021·Journal of Cellular and Molecular Medicine·Chinasa Valerie OlovoMin Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.